Advertisement

Safety and feasibility of autologous cord blood infusion for improving motor function in young children with cerebral palsy in Japan: A single-center study

      Abstract

      Introduction

      Cerebral palsy (CP) is the most prevalent motor disorder of childhood. It typically results from in utero or perinatal brain injury. Recently, it has been reported that autologous cord blood (ACB) infusion for children with CP improved gross motor function and brain connectivity, but unfortunately, it has never been tried in Japan. We conducted a pilot study of the infusing of ACB, which was delivered from private bank, in the children with CP to assess the safety and feasibility to the procedure as well as any effect in improving neurological function.

      Methods

      After demonstrating the induction of tissue regeneration in animal model studies conducted a single-arm pilot study of intravenous ACB infusion in 6 young Japanese children with CP (ages 1–6 years). Primary outcomes were safety assessed by vital signs, clinical symptoms, and blood and urinary examinations at baseline and 1 weeks, 1, 2 and 3 years after treatment. In addition, motor function evaluations, neurodevelopmental examinations, magnetic resonance imaging, and electroencephalography (EEG) were performed at the same time.

      Results

      Infusion was generally well-tolerated, although one patient experienced microhematuria 1 year after treatment and another one patient experienced febrile convulsion once 9 months after treatment. These events were transient, no relapse was seen during observation study. All patients improved a median of 6.8 points on the 1-year Gross Motor Functional Measure-66 (GMFM-66) scores, greater than predicted by age and severity. Furthermore, the 2-year and 3-year GMFM-66 scores were also greater than expected (median 6.2 points and 5.5 points, respectively). Overall scales and language-social scales of the developmental quotient (DQ) improved in 3 of 6 patients, who had greater changes in their GMFM-66 scores than the other cases after treatment. There were no significant correlations among the GMFM-66 scores, DQ, and infusion cell counts.

      Conclusion

      ACB infusion was safe and feasible for clinical use in patients with CP. However, much more clinical study with larger numbers of patients and in-depth studies of treatment mechanism of CP are needed.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Brain and Development
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Matsmoto T.
        • Mugishima H.
        Non-hematopoietic stem cells in umbilical cord blood.
        Int J Stem Cell. 2009; 2: 83-89
        • Sun J.M.
        • Song A.W.
        • Case L.
        • Mikati M.
        • Gustafson K.E.
        • Simmons R.
        • et al.
        Effect of autologous cord blood infusion on motor function and brain connectivity in young children with cerebral palsy: A randomized, placebo-controlled trial.
        Stem Cell Transl Med. 2017; 6: 2071-2078
        • Kang M.
        • Min K.
        • Jang J.
        • Kim S.C.
        • Kang M.S.
        • Jang S.J.
        • et al.
        Involvement of immune response in the efficacy of cord blood cell therapy for cerebral palsy.
        Stem Cell Develop. 2015; 24: 2259-2268
        • Broxmeyer H.E.
        Biology of cord blood cells and future prospects for enhanced clinical benefit.
        Cytotherapy. 2005; 7: 209-2018
        • Phuc P.V.
        • Ngoc V.B.
        • Lam D.H.
        • Tam N.T.
        • Viet P.Q.
        • Ngoc P.K.
        Isolation of three important types of stem cells from the same samples of banked umbilical cord blood.
        Cell Tissue Bank. 2012; 13: 341-351
        • Novak I.
        • Walker K.
        • Hunt R.W.
        • Wallace E.M.
        • Fahey M.
        • Badawi N.
        Concise review: Stem cell interventions for people with cerebral palsy: systemic review with meta-analysis.
        Stem Cells Transl Med. 2016; 5: 1014-1025
        • Wang F.
        • Baba N.
        • Shen Y.
        • Yamashita T.
        • Tsuru E.
        • Tsuda M.
        • et al.
        CCL11 promotes migration and proliferation of mouse neural progenitor cells.
        Stem Cell Res Ther. 2017; 8: 26
        • Baba N.
        • Wang F.
        • Iizuka M.
        • Shen Y.
        • Yamashita T.
        • Takaishi K.
        • et al.
        Induction of regional chemokine expression in response to human umbilical cord blood cell infusion in the neonatal mouse ischemia-reperfusion brain injury model.
        PLoS ONE. 2019; 14https://doi.org/10.1371/journal.pone.0221111
        • Hanna S.E.
        • Bartlett D.J.
        • Rivard L.M.
        • Russell D.L.
        Reference curves for the gross motor function measure: Percentiles for clinical description and tracking over time among children with cerebral palsy.
        Phys Ther. 2008; 88: 596-607
        • Russell D.J.
        • Rosenbaum P.L.
        • Wright M.
        • Avery L.M.
        Clinics in Developmental Medicine. Gross Motor Function Measure (GMFM-66 & GMFM-88) user’s manual.
        2nd ed. Mac Keith Press, London2013
        • Rubinstein P.
        • Dobrila L.
        • Rosenfield R.E.
        • Adamson J.W.
        • Migliaccio G.
        • Migliaccio A.R.
        • Taylor P.E.
        • Stevens C.E.
        Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution.
        Proc Natl Acad Sci USA. 1995; 92: 10119-10122
        • Kato T.
        • Mandai T.
        • Iwatani S.
        • Koda T.
        • Nagasawa M.
        • Fujita K.
        • Kurokawa D.
        • Yamana K.
        • Nishida K.
        • Taniguchi-Ikeda M.
        • Tanimura K.
        • Deguchi M.
        • Yamada H.
        • Iijima K.
        • Morioka I.
        Extremely preterm infants small for gestational age are at risk for motor impairment at 3 years corrected age.
        Brain Develop. 2016; 38: 188-195
      1. Kaufman AS, Flanagan DP, Alfonso VC, Mascolo J. Test Review: Wechsler Intelligence Scale for Children, Fourth Edition (WISC-IV). J Psychoedu Assess 2006; 24: 278-295.

        • Oefflnger D.
        • Bagley A.
        • Rogers S.
        • Gorton G.
        • Kryscio R.
        • Abel M.
        • Damiano D.
        • Barnes D.
        • Tylkowski C.
        Outcome tools used for ambulatory children with cerebral palsy: responsiveness and minimum clinically important differences.
        Develop Med Child Neurol. 2008; 50: 918-925
        • Min K.
        • Song J.
        • Kang Y.
        • Ko J.
        • Ryu L.S.
        • Kang M.S.
        • Jang S.J.
        • Kim S.H.
        • Oh D.
        • Kim K.
        • Kim S.S.
        • Kim M.Y.
        Umbilical cord blood therapy potentiated with erythropoietin for children with cerebral palsy: A double-blind, randomized, placebo-controlled trial.
        Stem Cells. 2013; 31: 581-591
        • Englander Z.A.
        • Sun J.
        • Case L.
        • Mikati M.A.
        • Kurtzberg J.
        • Song A.W.
        Brain structural connectivity increase concurrent with functional improvement: Evidence from diffusion tensor MRI in children with cerebral palsy during therapy.
        Neuroimage: Clin. 2015; 7: 315-324
        • McDonald C.A.
        • Fahey M.C.
        • Jenkin G.
        • Miller S.L.
        Umbilical cord blood cells for treatment of cerebral palsy; timing and treatment options.
        Pediatr Res. 2018; 83: 333-344
        • Jiao Y.
        • Li X.-Y.
        • Liu J.
        A new approach to cerebral palsy treatment: Discussion of the effective components of umbilical cord blood and its mechanisms of action.
        Cell Transpl. 2019; 28: 497-509
        • Boruczkowski D.
        • Pujal J.-M.
        • Zdolinska-Malinowska I.
        Autologous cord blood in children with cerebral palsy: A review.
        Int J Mol Sci. 2019; 20: 2433
        • Peng X.
        • Song J.
        • Li B.
        • Zhu C.
        • Wang X.
        Umbilical cord blood stem cell therapy in premature brain injury: opportunities and challenges.
        J Neuro Res. 2020; 98: 815-825